<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920203</url>
  </required_header>
  <id_info>
    <org_study_id>NI 13007</org_study_id>
    <nct_id>NCT02920203</nct_id>
  </id_info>
  <brief_title>Genetic Autopsy and Sudden Death</brief_title>
  <acronym>AGEMOS</acronym>
  <official_title>Genetic Autopsy and Sudden Death of Young Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pathology department and forensic Institute, Raymond Poincaré hospital, Garches</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Referal Center for Inherited cardiac diseases, Pitié Salpêtrière Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical research Unit, Ambroise Paré Hospital, Boulogne Billancourt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiogenetic and molecular and cellular myogenetic functionnal unit Pitié Salpêtrière hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molecular and medical Virology Laboratory, Medical School, Reims</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to better identify hereditary cardiac causes of sudden unexpected&#xD;
      death in young subjects through Next-Generation Sequencing of autopsy tissue&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monitoring :&#xD;
&#xD;
      For index cases group, all the data will be monitored. For the relatives group, only the&#xD;
      informed consent will be monitored&#xD;
&#xD;
      Statistical analysis :&#xD;
&#xD;
        -  Evaluate the additional elucidation rate of unexpected sudden death&#xD;
&#xD;
        -  Evaluate causes obtained by Next Generation Sequencing (NGS) ( in comparison with&#xD;
           conventional autopsy (macroscopic and / or microscopic)&#xD;
&#xD;
        -  Descriptive study of the causes of sudden unexpected death, identified hereditary&#xD;
           cardiac causes percentages compared via various diagnostic approaches&#xD;
&#xD;
        -  Cost-effectiveness analysis&#xD;
&#xD;
      Data Management :&#xD;
&#xD;
      A database is created for the AGEMOS study with control of the discrepancies. All the index&#xD;
      cases' data entered in the data base will be double checked&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of sudden death elucidation rate obtained by high throughput sequencing (NGS) versus conventional autopsy (macroscopic and / or microscopic)</measure>
    <time_frame>27 months</time_frame>
    <description>Aim is to determine if elucidation rate of unexpected sudden death causes obtained by high throughput sequencing (NGS) is significantly better than conventional autopsy (macroscopic and / or microscopic) alone.&#xD;
Inclusion of a series of 100 consecutive and exhaustive cases (index cases) recruited by forensic institutes or pathology departements.&#xD;
Determine the rate of sudden death elucidation after NGS (after targeted capturing of 100 genes responsible for inherited cardiac diseases, including cardiomyopathy and electrical diseases) and comparison of sudden death elucidation rate obtained with conventional autopsy (macroscopic and microscopic) by chi 2 analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the epidemiology of causes of sudden death</measure>
    <time_frame>27 months</time_frame>
    <description>Inclusion of a serie of consecutive and exhaustive subjects recruited by forensic institutes or pathology departements.&#xD;
Determination all the causes of death after conventional autopsy (unnatural, toxicological, non-cardiovascular, vascular, cardiological and coronary, cardiological and non-coronary causes such as cardiomyopathies &amp; myocarditis, no cause identified Descriptive analysis. All quantitative data will be analyzed with the average, standard deviation and median.&#xD;
Frequencies and Clopper-Pearson confidence interval of 95% will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of elucidation rates of cause of sudden death including systematic cardiac screening in relatives</measure>
    <time_frame>39 months</time_frame>
    <description>Aim is to determine the impact of systematic family cardiac screening in the understanding of sudden deaths Comparison of elucidation rates of cause of sudden death according to three methods:&#xD;
i) identification of a hereditary heart disease via the systematic cardiac screening performed in relative; ii) by the conventional autopsy; iii) by sequencing NGS analysis; Statistics: test of McNemar (mated series). The threshold for level of statistical significance is chosen at 5 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic modeling of the various diagnostic approaches</measure>
    <time_frame>39 months</time_frame>
    <description>Cost-effectiveness modeling evaluation of medical and economic impact of the genetic molecular autopsy, efficacy being estimated by years of life saved in the family</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sudden Death</condition>
  <arm_group>
    <arm_group_label>index cases group</arm_group_label>
    <description>unexpected sudden death cases recruited by forensic institutes or pathology departements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>first degree relatives group</arm_group_label>
    <description>Relatives enrolled of unexpected sudden death index cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Heart and spleen tissue</intervention_name>
    <description>genetic sequencing</description>
    <arm_group_label>index cases group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Heart and spleen tissue (from autopsy)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Index cases enrolled: series of consecutive and exhaustive cases recruited by forensic&#xD;
        institutes or pathology departements Relatives enrolled: as many as possible during the&#xD;
        recruitment period&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Index cases :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects of more than 2 years old and less than 41 years old&#xD;
&#xD;
          -  Sudden unexpected death from natural and nontraumatic causes&#xD;
&#xD;
          -  Macroscopic autopsy performed within 72 hours after death and without signs of body&#xD;
             decomposition&#xD;
&#xD;
          -  No extracardiac obvious causes, including toxicological analysis when available&#xD;
&#xD;
          -  No significant coronary cause after autopsy (such as tight coronary stenosis,&#xD;
             congenital abnormality of the arteries, coronary vasculitis)&#xD;
&#xD;
          -  Informed consent of the close relation (family/reliable person) and / or legal&#xD;
             representative&#xD;
&#xD;
        Relatives :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  To be a first degree relative (parents, sister, brother, child) of a deceased subject&#xD;
             included in the AGEMOS study and accept to perform medical examination and transmit&#xD;
             results of examination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffroy Lorin de la Grandmaison, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hoptiaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Charron, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>+33 (0)1 42 16 13 47</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geoffroy Lorin de la Grandmaison, Pr</last_name>
    <phone>+33(0)1 47 10 76 90</phone>
    <email>g.lorin@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Charron, MD, PhD</last_name>
    <phone>+33 (0)1 42 16 13 47</phone>
    <email>philippe.charron@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Raymond Poincaré hospital</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffroy Lorin de la Grandmaison, Pr</last_name>
      <phone>+33(0)1 47 10 76 90</phone>
      <email>g.lorin@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sudden unexpected death</keyword>
  <keyword>young subjects</keyword>
  <keyword>molecular genetic autopsy</keyword>
  <keyword>sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Death</mesh_term>
    <mesh_term>Death, Sudden</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

